/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR
DISSEMINATION IN THE UNITED STATES./
TORONTO, March 11, 2014 /CNW/ - Concordia Healthcare Corp. ("Concordia") (TSX: CXR), is pleased to announce that it has closed its previously
announced short form prospectus offering, on a "bought deal" basis, of
5,750,000 common shares (the "Common Shares") of Concordia, which includes the exercise by the Underwriters (as
defined below) of an over-allotment option of 15%, for aggregate gross
proceeds of $67,562,500 (the "Offering"). The Offering was completed at a price per Common Share of $11.75 by
a syndicate of underwriters co-led by GMP Securities L.P. and Canaccord
Genuity Corp. and including Barclays Capital Canada Inc., Beacon
Securities Limited and Cormark Securities Inc.
Concordia is a diverse healthcare company focused on legacy
pharmaceutical products, orphan drugs and medical devices for the
diabetic population. The company's legacy pharmaceutical business
consists of an ADHD-treatment drug, Kapvay® (clonidine extended release
tablets), Ulesfia® (benzyl alcohol) Lotion a Head Lice Treatment, and
an Asthma-related medication, Orapred ODT® (prednisolone sodium
phosphate orally disintegrating tablets). Concordia's Specialty
Healthcare Distribution (SHD) division (Complete Medical Homecare)
distributes medical supplies targeting diabetes and related conditions.
Concordia's orphan division, Pinnacle, markets Photofrin® in the United
Concordia operates out of facilities in Oakville, Ontario, Lenexa,
Kansas (near Kansas City, Missouri), Bannockburn, (near Chicago),
Illinois and Bridgetown, Barbados.
SOURCE: Concordia Healthcare Corp.
For further information:
please visit www.concordiarx.com or contact:
Kristen Van Vogt
416-815-0700 x 244
416-815-0700 x 225